Cardiovasc Diabetol
-
Cardiovasc Diabetol · Jan 2013
Meta AnalysisCardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators. ⋯ A pooled analysis of 25 randomised clinical trials does not indicate that treatment with sitagliptin increases cardiovascular risk in patients with type 2 diabetes mellitus. In a subanalysis, a higher rate of cardiovascular-related events was associated with sulphonylurea relative to sitagliptin.